Navigation Links
Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference
Date:6/10/2008

T1. In addition to being Isis' first antisense drug for a kidney target, ISIS 388626 is also unique due to its 12 nucleotide length rather than the more typical 18 - 21 nucleotide sequences that comprise Isis' other drugs. This attribute simplifies manufacturing and has the potential to substantially reduce related expenses. The short sequence may also contribute to ISIS 388626's unusually high potency; it is among the most potent antisense drugs that Isis has evaluated in preclinical models.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding the therapeutic and commercial potential of Isis' technologies and products in development for the treatment of metabolic diseases. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
2. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
3. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
8. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
9. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
10. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
11. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  As physicians ... to digital communication channels to learn about new ... finding – from a new report by global ... – shows that communicating via a customized mix ... provides the best opportunity to engage with physicians. ...
(Date:9/23/2014)... -- Enable Injections , developer of a novel ... and nearly painless for patients to self-inject large-dose biologic ... named winner of the ,Buzz of BIO Investor Forum, ... Enable is one of only two ,Buzz ... votes in the "Late Stage Leaders" category.  ...
(Date:9/23/2014)... 2014 Avillion LLP, a ... of Jarrod Longcor as Chief Business ... for structuring, negotiating and executing successful strategic alliances, ... providing management and strategic leadership to the organisation. ... team. Mr Longcor brings to Avillion ...
Breaking Medicine Technology:As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... Intra-Cellular Therapies, Inc. (ITI),today announced it has initiated ... using its drug candidate ITI-722. ITI-722 acts predominantly,as ... important new,approach to the treatment of SMI. Because ... modulatory activities, ITI believes, ITI-722 can be,used not ...
... Research Is a Winning Pursuit, WASHINGTON, Dec. ... L. Trull President, Foundation for Biomedical,Research:, Biomedical ... of pursuit" in 1980 earned Mario Capecchi a ... setback, the Harvard-educated genetics professor,persisted toward his goal. ...
Cached Medicine Technology:Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 2Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 3Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 4Nobel Prize-Winning Discovery 2Nobel Prize-Winning Discovery 3
(Date:9/23/2014)... The Fit Body Boot Camp franchise is known throughout ... and their community outreach. The new Rockville Fit Body Boot ... of the company’s new fitness boot camp in ... is excited about the grand opening, because of the opportunity ... honor the memory of emergency workers who sacrificed their lives ...
(Date:9/23/2014)... 2014 Maturo Medical Weight and ... announced Dr. Lisa Maturo has received certification in ... Worldlink Medical Academy. Dr. Maturo is one of ... this credential. , World-renowned bioidentical hormone replacement ... the rigorous training course, which trained participants in ...
(Date:9/23/2014)... 23, 2014 Wohl Associates ... packaging equipment, has recently taken delivery of used industrial ... include mixers, sheeters, and equipment for producing gnocchi and ... Toresani unit and a La Parmigiana mixer/extruder. With a ... a mixing tank that is 17” wide, 28” long ...
(Date:9/23/2014)... 23, 2014 Hope For The Warriors® ... Celebration to be hosted in Boston, Massachusetts on Sunday, ... Amphitheater. This signature event honors the courage of our ... the fallen. Proceeds from the evening will benefit Hope ... a sense of self, restoring the family unit, and ...
(Date:9/23/2014)... Los Angeles, CA (PRWEB) September 23, 2014 ... launched sales funnel building software application has created a ... commotion surrounding the launch of this new software has ... published an investigative review for her readers. ... such as site design, programming and development can be ...
Breaking Medicine News(10 mins):Health News:Rockville Fit Body Boot Camp Invites Community to Fitness Boot Camp Grand Opening 2Health News:Rockville Fit Body Boot Camp Invites Community to Fitness Boot Camp Grand Opening 3Health News:Doctor Lisa Maturo of Maturo Medical Obtains Expert Certification in BioIdentical Hormone Replacement Therapy from World Link Medical 2Health News:Used Industrial Pasta Machinery Now Available at Wohl Associates 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3Health News:ClickFunnels 2.0 – Review Of Russell Brunson’s Sales Funnel Building Software Released 2
... Group,Inc. (Amex: QGP ) (http://www.QuantumMD.com ), ... Noel J. Guillama, President &,CEO, will present at ... p.m. (Pacific) on Monday, August 18, 2008 at ... Guillama will give a 23-minute presentation regarding The ...
... a national survey,of adults, 60 percent of Hispanic American ... is the #1 fatal disease among women.,Further, nearly half ... greater than that of Caucasian women. Dania Rich-Spencer, Vice,President ... the Go,Red For Women, founded by the American Heart ...
... getting infected cells to drop their guard according to ... a catalyst to a cancer-busting reaction which calls up an ... Cancer adapts quickly to traditional drugs which attack infected cells ... of defence using ruthenium as a catalyst to a reaction ...
... School of Medicine, Fox Chase Cancer Center and ... that will speed the translation of medical and ... , As part of the agreement, the ... Translational Medicine, based at Temple, to design and ...
... Program to Increase Breast and ... Cervical Cancer Screening Rates, COLUMBIA, ... care guidance company, today announced the,launch of their Women,s Health ... to help increase the,prevention and early detection of breast and ...
... all evidence of disease in selected patients with cancer ... the first published report from an ongoing clinical trial. ... Clinical Cancer Research, (published online August 12) researchers ... targeted radiation therapy had completely controlled all signs of ...
Cached Medicine News:Health News:The Quantum Group to Present at the Noble Financial Equity Conference 2Health News:The Quantum Group to Present at the Noble Financial Equity Conference 3Health News:Temple, Fox Chase and Geisinger create Keystone Institute for Translational Medicine 2Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 2Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 3Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 4Health News:Targeted radiation therapy can control limited cancer spread 2Health News:Targeted radiation therapy can control limited cancer spread 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: